Cytokinetics Inc’s recent filing unveils that its Director WIERENGA WENDALL unloaded Company’s shares for reported $36069.0 on Dec 16 ’24. In the deal valued at $48.61 per share,742 shares were sold. As a result of this transaction, WIERENGA WENDALL now holds 24,559 shares worth roughly $1.2 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, WENDELL WIERENGA bought 742 shares, generating $36,069 in total proceeds.
Before that, HENDERSON JOHN T sold 1,780 shares. Cytokinetics Inc shares valued at $89,748 were divested by the Director at a price of $50.42 per share. As a result of the transaction, HENDERSON JOHN T now holds 38,461 shares, worth roughly $1.89 million.
RBC Capital Mkts initiated its Cytokinetics Inc [CYTK] rating to an Outperform in a research note published on November 08, 2024; the price target was $80. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in mid August from “a Buy” to “a Neutral”. UBS also remained covering CYTK and has decreased its forecast on January 24, 2024 with a “Neutral” recommendation from previously “Buy” rating. Morgan Stanley revised its rating on January 05, 2024. It rated CYTK as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of CYTK
On Monday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock jump 0.76% to $49.02. Over the last five days, the stock has lost -2.93%. Cytokinetics Inc shares have fallen nearly -41.29% since the year began. Nevertheless, the stocks have risen 33.90% over the past one year. While a 52-week high of $110.25 was reached on 01/08/24, a 52-week low of $32.70 was recorded on 05/28/24. SMA at 50 days reached $52.58, while 200 days put it at $57.43.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 48.51, which if violated will result in even more drops to 48.01. On the upside, there is a resistance level at 49.55. A further resistance level may holdings at 50.09. The Relative Strength Index (RSI) on the 14-day chart is 40.39, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.39, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 81.28%. Stochastics %K at 27.20% indicates the stock is a holding.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2024-11-29, dropping by -1.66 million shares to a total of 14.03 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 15.69 million shares. There was a decline of -11.83%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 09, 2023 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $50 price target.
